An independent 24-week , randomized controlled trial of 303 adult patients with asthma who are at risk , which compared the efficacy of SMART ( single budesonide-formoterol inhaler as maintenance and reliever therapy ) with a fixed-dose regimen with salbutamol as reliever ( `` Standard '' ) .